Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Linda G. Mellbin; Deepak L. Bhatt; Jens Peter David; Kathrine Ekström; Mark C. Petrie; Søren Rasmussen; Tina Vilsbøll

doi:10.1093/eurheartj/ehae028

Semaglutide and cardiovascular outcomes by baseline HbA_1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Linda G. Mellbin^*, Deepak L. Bhatt, Jens Peter David, Kathrine Ekström, Mark C. Petrie, Søren Rasmussen, Tina Vilsbøll

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

13 Citations (Scopus)

22 Downloads (Pure)

Original language	English
Journal	European Heart Journal
Volume	45
Issue number	15
Pages (from-to)	1371-1374
Number of pages	4
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehae028
Publication status	Published - 2024
Externally published	Yes

Keywords

Cardiovascular outcomes trial
Glucagon-like peptide-1 receptor agonist
HbA
Major adverse cardiovascular events
PIONEER 6
Post hoc analysis
Semaglutide
SUSTAIN 6
Type 2 diabetes

Access to Document

10.1093/eurheartj/ehae028Licence: CC BY

FulltextFinal published version, 306 KBLicence: CC BY

Library access?

Check availability at the Royal Danish Library

Cite this

@article{ec2ca972ba3e4d5a985b9a3e5db3f7ae,

title = "Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials",

keywords = "Cardiovascular outcomes trial, Glucagon-like peptide-1 receptor agonist, HbA, Major adverse cardiovascular events, PIONEER 6, Post hoc analysis, Semaglutide, SUSTAIN 6, Type 2 diabetes",

author = "Mellbin, {Linda G.} and Bhatt, {Deepak L.} and David, {Jens Peter} and Kathrine Ekstr{\"o}m and Petrie, {Mark C.} and S{\o}ren Rasmussen and Tina Vilsb{\o}ll",

note = "Funding Information: This study was funded by Novo Nordisk. ",

year = "2024",

doi = "10.1093/eurheartj/ehae028",

language = "English",

volume = "45",

pages = "1371--1374",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "15",

}

TY - JOUR

T1 - Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes

T2 - the SUSTAIN 6 and PIONEER 6 trials

AU - Mellbin, Linda G.

AU - Bhatt, Deepak L.

AU - David, Jens Peter

AU - Ekström, Kathrine

AU - Petrie, Mark C.

AU - Rasmussen, Søren

AU - Vilsbøll, Tina

N1 - Funding Information: This study was funded by Novo Nordisk.

PY - 2024

Y1 - 2024

KW - Cardiovascular outcomes trial

KW - Glucagon-like peptide-1 receptor agonist

KW - HbA

KW - Major adverse cardiovascular events

KW - PIONEER 6

KW - Post hoc analysis

KW - Semaglutide

KW - SUSTAIN 6

KW - Type 2 diabetes

U2 - 10.1093/eurheartj/ehae028

DO - 10.1093/eurheartj/ehae028

M3 - Journal article

C2 - 38416593

AN - SCOPUS:85190494167

SN - 0195-668X

VL - 45

SP - 1371

EP - 1374

JO - European Heart Journal

JF - European Heart Journal

IS - 15

ER -